Navigation Links
Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
Date:8/19/2007

PALO ALTO, Calif., Aug. 15 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that new guidelines, developed jointly by the American College of Cardiology Foundation and the American Heart Association and published in this week's issue of Circulation, state that, "ranolazine may be safely administered for symptom relief after UA/NSTEMI."

Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates. The product has not been determined by regulatory authorities to be safe and effective for any other use.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics' clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to treatment guidelines, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE CV Therapeutics, Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. siRNA Design Guidelines
2. Federal and global guidelines on stem cell research offer a level playing field
3. With ethics guidelines, political consensus emerging on stem-cell research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... 25, 2017 , ... Studying biological events while they happen ... imaging using fluorescence microscopy is the perfect approach to explore these complex questions. ... be discussed, from small animal models and tissues to individual organelle and protein ...
(Date:5/24/2017)... ... May 23, 2017 , ... Triumph ... modular buildings, announced the launch of the Mobile Big Room. This state-of-the-art ... help support on-site teamwork and collaboration. , The Mobile Big Room enables ...
(Date:5/23/2017)... ... 23, 2017 , ... Firmex today announced the ... easy for organizations to send and gather large files and confidential documents beyond ... file size limitations. , Using the same market-tested infrastructure as Firmex’s flagship ...
(Date:5/23/2017)... Hong Kong (PRWEB) , ... May 22, 2017 ... ... the third year in a row in the Aragon Research Globe™ for Corporate ... that align with industry direction and market demand, and effectively perform against those ...
Breaking Biology Technology:
(Date:4/17/2017)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... 2016 Annual Report on Form 10-K on Thursday April 13, 2017 ... ... Investor Relations section of the Company,s website at http://www.nxt-id.com  under ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):